Anti-cGKI抗体- Carboxyterminal end (ab37709)

概述

  • 产品名称Anti-cGKI抗体- Carboxyterminal end
    参阅全部 cGKI 一抗
  • 描述
    兔多克隆抗体to cGKI - Carboxyterminal end
  • 经测试应用适用于: ELISA, WB, IHC-P, ICC/IFmore details
  • 种属反应性
    与反应: Mouse, Human
  • 免疫原

    Synthetic peptide conjugated to KLH, located within C terminal amino acids 600-670 of Human cGKI

  • 阳性对照
    • 293 cell lysate. Mouse small intestine tissue lysate.

性能

相关产品

应用

Our Abpromise guarantee covers the use of ab37709 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
ELISA 1/1000.
WB 1/100 - 1/500. Predicted molecular weight: 76 kDa.
IHC-P 1/50 - 1/100.
ICC/IF 1/50. PubMed: 22158710

靶标

  • 功能Serine/threonine protein kinasethat acts as key mediator of the nitric oxide (NO)/cGMP signaling pathway. GMP binding activates PRKG1, which phosphorylates serines and threonines on many cellular proteins. Numerous protein targets for PRKG1 phosphorylation are implicated in modulating cellular calcium, but the contribution of each of these targets may vary substantially among cell types. Proteins that are phosphorylated by PRKG1 regulate platelet activation and adhesion, smooth muscle contraction, cardiac function, gene expression, feedback of the NO-signaling pathway, and other processes involved in several aspects of the CNS like axon guidance, hippocampal and cerebellar learning, circadian rhythm and nociception. Smoth muscle relaxation is mediated through lowering of intracellular free calcium, by desensitization of contractile proteins to calcium, and by decrease in the contractile state of smooth muscle or in platelet activation. Regulates intracellular calcium levels via several pathways: phosphorylates MRVI1/IRAG and inhibits IP3-induced Ca(2+) release from intracellular stores, phosphorylation of KCNMA1 (BKCa) channels decreases intracellular Ca(2+) levels, which leads to increased opening of this channel. PRKG1 phosphorylates the canonical transient receptor potential channel (TRPC) family which inactivates the associated inward calcium current. Another mode of action of NO/cGMP/PKGI signaling involves PKGI-mediated inactivation of the Ras homolog gene family member A (RhoA). Phosphorylation of RHOA by PRKG1 blocks the action of this protein in myriad processes: regulation of RHOA translocation; decreasing contraction; controlling vesicle trafficking, reduction of myosin light chain phosphorylation resulting in vasorelaxation. Activation of PRKG1 by NO signaling alters also gene expression in a number of tissues. In smooth muscle cells, increased cGMP and PRKG1 activity influence expression of smooth muscle-specific contractile proteins, levels of proteins in the NO/cGMP signaling pathway, down-regulation of the matrix proteins osteopontin and thrombospondin-1 to limit smooth muscle cell migration and phenotype. Regulates vasodilator-stimulated phosphoprotein (VASP) functions in platelets and smooth muscle.
  • 组织特异性Primarily expressed in lung and placenta.
  • 序列相似性Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. cGMP subfamily.
    Contains 1 AGC-kinase C-terminal domain.
    Contains 2 cyclic nucleotide-binding domains.
    Contains 1 protein kinase domain.
  • 结构域Composed of an N-terminal leucine-zipper domain followed by an autoinhibitory domain, which mediate homodimer formation and inhibit kinase activity, respectively. Next, two cGMP-binding domains are followed by the catalytic domain at the C-terminus. Binding of cGMP to cGMP-binding domains results in a conformational change that activates kinase activity by removing the autoinhibitory domain from the catalytic cleft leaving the catalytic domain free to phosphorylate downstream substrates. Isoforms alpha and beta have identical cGMP-binding and catalytic domains but differ in their leucine zipper and autoinhibitory sequences and therefore differ in their dimerization substrates and kinase enzyme activity.
    Heterotetramerization is mediated by the interaction between a coiled-coil of PRKG1 and the leucine/isoleucine zipper of PPP1R12A/MBS, the myosin-binding subunit of the myosin phosphatase.
  • 翻译后修饰Autophosphorylation increases kinase activity.
    65 kDa monomer is produced by proteolytic cleavage.
  • 细胞定位Cytoplasm. Colocalized with TRPC7 in the plasma membrane.
  • Information by UniProt
  • 数据库链接
  • 别名
    • cGK 1 antibody
    • cGK1 antibody
    • cGKI alpha antibody
    • cGKI antibody
    • cGKI beta antibody
    • cGMP-dependent protein kinase 1 antibody
    • cGMP-dependent protein kinase I antibody
    • DKFZp686K042 antibody
    • FLJ36117 antibody
    • KGP1_HUMAN antibody
    • KGPB antibody
    • MGC71944 antibody
    • pkg antibody
    • PRKG1 antibody
    • PRKG1B antibody
    • PRKGR1A antibody
    • PRKGR1B antibody
    see all

Anti-cGKI antibody - Carboxyterminal end 图像

  • Immunohistochemical detection of PKG expression in formalin-fixed and paraffin-embedded human hepatocarcinoma tissue using 1/50 ab37709.
  • Lane 1 : Anti-cGKI antibody - Carboxyterminal end (ab37709) at 1/100 dilution
    Lane 2 : Anti-cGKI antibody - Carboxyterminal end (ab37709) at 1/1000 dilution

    Lane 1 : 293 cell lysate
    Lane 2 : mouse small intestine tissue lysate


    Predicted band size : 76 kDa
    Observed band size : 76 kDa
    Additional bands at : 20 kDa,30 kDa. We are unsure as to the identity of these extra bands.

Anti-cGKI antibody - Carboxyterminal end (ab37709)参考文献

This product has been referenced in:
  • Zhang DX  et al. H2O2-induced dilation in human coronary arterioles: role of protein kinase G dimerization and large-conductance Ca2+-activated K+ channel activation. Circ Res 110:471-80 (2012). WB, ICC/IF, IHC-P ; Human . Read more (PubMed: 22158710) »

See 1 Publication for this product

Product Wall

There are currently no Abreviews or Questions for ab37709.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"